Resistant Hypertension Clinical Trial
Official title:
Adrenal Artery Ablation Treats Primary Aldosteronism With Resistant Hypertension (AAA-RHT)
Verified date | April 2020 |
Source | Third Military Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary aldosteronism(PA) is the most common endocrine cause of resistant hypertension.
Surgery and medicine are the main treatment for PA by the current guidelines. However,only a
small part of patients with PA meet the surgical criteria, and most of them have to take
spironolactone or other antihypertensive drugs for long time. On the other side, long-term
inhibition of aldosterone receptor may cause hyperkalemia, male breast hyperplasia and other
adverse reactions. Moreover, hyperaldosterone is still not corrected by spironolactone, which
cause extensive cerebrovascular damages even though blood pressure and blood potassium had
been normalized.
With the development of adrenal vein sampling and adrenal ablation, the precise diagnosis and
treatment of PA is possible. Selective adrenal artery ablation (AAA) was observed with
significant decrease of blood aldosterone and blood pressure in patients with PA, which made
it promissing that primary aldosteronism with resistant hypertension could be relieved by
adrenal artery ablation.
Status | Completed |
Enrollment | 36 |
Est. completion date | October 15, 2019 |
Est. primary completion date | April 15, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Male or female, age between 30-65 years old. - Primary aldosteronism with resistant hypertension. - Informed consent signed and agreed to participate in this trial. Exclusion Criteria: - Secodary hyertension due to other causes. - History of depression,schizophrenia or vascular dementia . - History of cardio-cerebral vascular events such as congestive heart failure, myocardial infarction or stroke within 3 months. - Hypohepatia (AST or AST is twice higher than the upper limit) or history of hepatitis or cirrhosis, hepatic encephalopathy. - Renal insufficiency ( serum creatinine is 1.5 times higher than the upper limit) or history of dialysis and nephritic syndrome. - Acute infections, tumor, severe arrhythmia, mental disorders, alcohol or medicine addiction. - Fertile woman without contraceptives. - Any surgical or medical conditions that significantly influence absorption, distribution, metabolism or excretion of the anti-hypertensive drugs. - Allergic to or have contraindication to the contrast agents and alcohol. |
Country | Name | City | State |
---|---|---|---|
China | The third hospital affiliated to the Third Military Medical University | Chongqing |
Lead Sponsor | Collaborator |
---|---|
Third Military Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of office systolic blood ptressure | Change of office systolic blood pressure compared with baseline after 24 weeks. | 24 weeks | |
Secondary | Change of office dystolic blood pressure | Change of office dystolic blood pressure compared with baseline after 24 weeks. | 24 weeks | |
Secondary | Change of home systolic blood pressure | Change of home systolic blood pressure compared with baseline after 24 weeks. | 24 weeks | |
Secondary | Change of home diastolic blood pressure | Change of home diastolic blood pressure compared with baseline after 24 weeks. | 24 weeks | |
Secondary | Change of 24-h average systolic blood pressure | Change of 24-h average systolic blood pressure compared with baseline after 24 weeks. | 24 weeks | |
Secondary | Change of 24-h average diastolic blood pressure | Change of 24-h average diastolic blood pressure compared with baseline after 24 weeks. | 24 weeks | |
Secondary | Change of DDD of anti-hypertensive regimen | Change of Defined Daily Dose (DDD) of anti-hypertensive regimen compared with baseline after 24 weeks. | 24 weeks | |
Secondary | Change of plasma adrenal hormones | Change of plasma aldosterone and cortisol compared with baseline after 24 weeks. | 24 weeks | |
Secondary | Change of plasma renin levels | Change of plasma renin levels compared with baseline after 24 weeks. | 24 weeks | |
Secondary | Change of blood electrolytes | Change of serum potassium, natrium, and chlorine compared with baseline after 24 weeks. | 24 weeks | |
Secondary | Change of serum creatinine | Change of serum creatinine measured as umol/L compared with baseline after 24 weeks. | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05545059 -
Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension
|
Phase 3 | |
Not yet recruiting |
NCT04388124 -
VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION
|
Phase 2 | |
Withdrawn |
NCT01939392 -
Rapid Renal Sympathetic Denervation for Resistant Hypertension II
|
Phase 2/Phase 3 | |
Recruiting |
NCT06228677 -
Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
|
||
Recruiting |
NCT04213963 -
Prospective Study on Primary Aldosteronism in Resistant Hypertension
|
||
Recruiting |
NCT05563077 -
Aerobic Exercise and Resistant Hypertension
|
N/A | |
Recruiting |
NCT03758196 -
Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension(RSDARH)
|
N/A | |
Active, not recruiting |
NCT03179800 -
CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™
|
N/A | |
Completed |
NCT04519658 -
A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
|
Phase 2 | |
Not yet recruiting |
NCT05552300 -
Superselective Adrenal Arterial Embolization for Resistant Hypertension
|
N/A | |
Not yet recruiting |
NCT05426707 -
Remote Ischemic Conditioning for the Treatment of Resistant Hypertension
|
N/A | |
Active, not recruiting |
NCT05562934 -
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
|
Phase 2 | |
Recruiting |
NCT06034743 -
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
|
Phase 3 | |
Withdrawn |
NCT02926495 -
Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension.
|
N/A | |
Active, not recruiting |
NCT02670681 -
Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects
|
N/A | |
Completed |
NCT02572024 -
The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study)
|
N/A | |
Terminated |
NCT02295683 -
Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry
|
||
Completed |
NCT02001350 -
Carotid Ultrasound Study
|
N/A | |
Recruiting |
NCT04331691 -
Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension
|
Phase 4 | |
Recruiting |
NCT04637152 -
Sacubitril/Valsartan in Resistant Hypertension
|
Phase 2 |